SUMMARY One hundred and eight noninstitutionalised patients with Parkinson's disease were studied to find out whether the age of disease onset affects patients' cognitive, memory and psychomotor performance. "Early onset" patients (whose disease began before 60 years of age) showed a wide spectrum of impairments in neuropsychological performance compared with age-matched normal subjects. However, only one (2%) of these patients was demented according to DSM III criteria. Dementia was more frequent in patients with equivalent disease duration, but with late onset of disease (over 60 years); 13 of such patients (25%) were demented. The present study supports previous findings which show that dementia increases with advancing age in Parkinson's disease. It also suggests that cognitive changes are also found in patients with early onset of disease.
The great variation in the cognitive performance of individual patients and the differences in the severity of their extrapyramidal symptoms has given rise to the idea that idiopathic Parkinson's disease may encompass several subgroups. Some studies13 indicate that dementia, greater motor disability and rapid symptom progression are linked with a later age of onset. Thus the existence of two groups has been suggested: a late onset "malignant" form and an early onset "benign" form of Parkinson's disease. The issue is controversial, however. Mjones4 observed the opposite to be the case, whereas Lesser et al reported that individuals affected more severely are younger and have a shorter disease duration, and Hoehn and Yahr6 found no connection between the age of onset and progression of the disease. These studies were not based on formal neuropsychological evaluation but on brief estimations of mental state, which are recognised as carrying a high false-positive rate. We have endeavoured to determine whether more comprehensive formal neuropsychological evaluation of cognitive functions could clarify the role of age at disease onset in modifying the cognitive performance and disease progression.
A total of 108 outpatients with Parkinson's disease between 32 and 86 years of age were studied, in whom the age of onset, whether below 60 years ("early onset") or over 60 years ("late onset"), could be estimated within an accuracy of at least 6 months. The distribution of age at onset is given in table 1. The clinical data on the patients are given in table 2 which shows that the duration of disease was equal in the two groups. These patients were selected by excluding those in whom the duration of disease exceeded 10 years or in whom the duration of disease obtained from the patient and his relatives, could not be verified from hospital or health care records. Furthermore, subjects with other diseases with possible adverse effects on cognitive performance were excluded from the study. Patients with controlled cardiac insufficiency and/or arterial hypertension were accepted. Of drugs with central nervous system effects, only treatment with small amounts of benzodiazepines and tricyclics, was allowed. Levodopa, with or without a decarboxylase inhibitor, anticholinergic drugs, amantadine and 1-deprenyl (selegiline) were allowed. Since anticholinergic drugs have The effect of age of disease onset on neuropsychological performance in Parkinson's disease The patients' performance was compared with that of 55 healthy control subjects, mainly spouses of the patients but also healthy volunteers from a church bible group, matched for educational level and age. The same criteria for inclusion and exclusion were used as in patient selection. Of the total of 55 control subjects 20 were under 60 (47-4 + 7-0, mean ± SD) and 35 over 60 (71-8 + 7-7, mean + SD) years of age.
Clinical neurological disability was evaluated using the Columbia University Parkinsonism Disability Rating Scale,'0 modified to include arm swing during walking. A score of 0 to 4 (0 = normal, 4 = maximal disability) was given separately for tremor and rigidity. A composite score for bradykinesia was derived by adding the scores for posture, gait, balance, finger dexterity, alternating movements, rising from a chair, facial expression and arm swing.
The neuropsychological studies consisted of tests measuring cognitive, memory and psychomotor functions. Cognitive functions were evaluated by using the subtests of similarities, picture completion and block design of the Wechsler" Adult Intelligence Scale (WAIS). The Wechsler Memory Scale I (WMS I) was used to evaluate memory functions using the subtests of digit span, logical memory, associative learning and visual memory. 12 Psychomotor functions were studied by measuring reaction time and movement time made with computer-controlled equipment. The movement and reaction time responses involved movement of the dominant hand over a distance of 32cm. The subjects held their index finger on a button ("go" button) and received visual signals indicating the direction of the intended movement (left or right target) and when to move ("GO" signal). In the test of simple reaction time (SRT), the direction signal (either left or right) came on 2 to 4 s before the "GO" signal, whereas in the choice reaction time (CRT) test, they came on at the same time. Direction of successive movements and movement intervals varied at random. A mean value of 16 trials was scored for each subject in each reaction time experiment. In the results, the reaction times (in ms) refer to the latency between the "GO" signal and the beginning of the movement, and movement time (MT) refers to time taken (in ms) for a finger to move from the "GO" button to either of the two targets. Additional tests of psychomotor performance included the Purdue pegboard test, finger tapping speed (number of taps/ Os) and writing time (the time it took, in seconds, for all subjects to write the same sentence). Stroop's colour test which is particularly sensitive in subjects with frontal lesions was also used to evaluate psychomotor function (speech), the ability to follow a complex plan and inhibition of irrelevant elements. ' WAIS (fig 2) . The patients performed worse than the control subjects in the logical memory (p < 0-01) and visual memory (p < 0.01) subtests of WMS I (fig 2) . Of the cognitive flexibility tests ( The Beck Depression Index for the patients with late onset was also (p < 0-001) higher (6-3 + 46, mean + SD) than in the control subjects (2-4 + 2-2, mean + SD). (2) whereas in similarities (1) andpicture completion (3) the difference was not significant. In memory tests the patients were inferior to the control subjects in logical memory (5, p < 0 01) and visual memory (7, p < 0 01) but not in associative learning (6) and digit span (4).
Comparison of the early and late onset Parkinsonism
The patients with late onset performed worse than those with early onset in all cognitive and memory functions (p < 0-01-0.001). They were also inferior in tests of cognitive flexibility and psychomotor capacity. The degree of depression was identical in the two groups. The inter-individual variation was more marked in the late onset group. Figure 3 illustrates the degree of variability in memory functions of the two groups.
To take into account possible age-related cognitive changes in the control subjects, the results were transformed into z-scores. The age-matched control subjects for both patient-groups were used as respective standard populations to represent the zero level. This data on WAIS and WMS I is shown in fig 4 and the results of the psychomotor measurements are given in fig 5. . The figures confirmed the results of previous comparisons showing that the early onset patients differentiated even more from their age-matched control group than the late onset patients from their controls. Statistically significant differences between the early and late onset patients were observed in picture completion (p < 001), associative learning (p < 0-01), movement time (p < 0-05), Stroop 3 (p < 0-001), Stroop 3-2 (p < 0 001), Trail making (p < 0 01), Purdue pegboard performance with both the dominant hand (p < 0001) and nondominant hand (p < 0 05) as well as bimanually (p < 0 001).
To study whether the differences between the early onset and late onset group would be even clearer at the most extreme age groups, patients with disease onset under 45 years of age were compared with those SIMIL BLOCK PICTC DIGSP LOGME ASSLE VISME According to DSM III criteria, 13 (25%) of the late onset patients were demented; the corresponding figure was one (2%) in the early onset group in spite of the similar duration of the disease.
A statistical analysis was also carried out after excluding the patients treated with anticholinergic drugs. At the time of the examination anticholinergic drugs were used by 13 patients in the early onset group and 17 patients in the late onset group. The exclusion of these subjects did not essentially change the results.
Discussion
Several clinical studies have reported that the frequency of dementia in patients with Parkinson's disease increases with advancing age,2 18 19 mental capacity being preserved in a younger patient population.20 Some authors' 3 have even postulated that there are two clinically and possibly pathologically distinct forms of idiopathic Parkinson's disease: younger patients have a relatively pure motor disorder with a longer and more benign course, and better response to levodopa treatment, whereas in older patients the symptom complex includes a motor disorder followed by cognitive decline with a more fulminant course and poor response to levodopa.
The present neuropsychological study indicates that the previous clinical impression, albeit valid in many respects, is not the whole truth. Our study also shows that the performance of the patients with late onset disease is significantly inferior to that of the patients with early onset. On the other hand, the patients with early onset disease also performed less well than their age-matched control subjects in a number of individual tests evaluating cognitive and memory functions. The memory deficit was evident in all tests requiring mental processing of material but not in a simple test of immediate retrieval (digit span). The same kind of memory pattern, distinguishing between effort-demanding and automatic memory processes, has previously been reported at an early stage of the disease in untreated patients.2' 22 Evaluation of cognitive functions showed that the patients with early disease onset have impairments in cognitive flexibility and in the ability to maintain a mental set, as has previously been reported in untreated patients at an early stage of the disease22 23 and in patients treated with levodopa. 24 Contrary to previous reports' 20 the early onset patients were thus impaired on several measures of cognitive and psychomotor functions. This difference in results was probably caused by the methods used to evaluate the patients' mental functions. We used formal neuropsychological methods, whereas the studies referred to were based on a brief mental status evaluation. These simple tests may well be suitable for revealing more profound impairments in mental ability, yet not sensitive enough for the discrimination of milder cognitive changes.
The degree of cognitive impairment and its variability in older patients deserves a separate comment. The various cognitive and memory functions of our late onset patients were significantly more impaired than those of early onset patients. In this respect, our results are consistent with the findings of Jellinger and Riederer25 that brain atrophy in Parkinson's disease is more closely associated with aging than with the duration of the disease. The differences between the early onset patients and age-matched normal controls in some subtests of memory functions (learning) and cognitive flexibility were not so clear in the late onset group in comparison with the control subjects. The reason for this is not clear, but could be, at least partially, that impairments in these functions are decline is extremely variable. One explanation for such variance in mental capacity of patients with late onset Parkinson's disease was provided by Quinn et a!27 who estimated that 5% of patients over 65 years with clinical Parkinson's disease would, by chance, have Alzheimer disease, and that an additional 10% or so might have combined pathology sufficient to cause dementia. Accordingly, a population with late onset Parkinson's disease may, as a consequence of independent age-related changes, have an additional risk of dementia.28
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